FI
APLS

Fosun International’s Apellis Pharmaceuticals APLS Stock Holding History

Fosun International’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-262,728
Closed -$6.42M – 236
2019
Q2 		$6.42M Sell
262,728
-32,000
-11% -$651K 0.42% 36
2019
Q1 		$5.62M Hold
294,728
– – 0.36% 44
2018
Q4 		$3.91M Buy
+294,728
New +$4.52M 0.23% 51

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Fosun International's APLS Position: Q3 2019 in Review

Fosun International sold out of Apellis Pharmaceuticals (APLS) in Q3 2019, closing a stake of 262,728 shares — an estimated $6.42M sold.

Fosun International first reported a position in APLS in Q4 2018 and held it in 3 quarters. The position peaked at $6.42M in Q2 2019. 129 funds tracked by Wall St. Rank hold APLS as of Q3 2019.

  • Fosun International reported no remaining Apellis Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 262,728 Apellis Pharmaceuticals shares in Q3 2019, an estimated $6.42M.
  • Fosun International first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Fosun International's Apellis Pharmaceuticals position peaked at $6.42M in Q2 2019.
  • 129 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.